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ABSTRACT
The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with 
Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality 
and morbidity in Heart Failure (HF) trial (PARADIGM-HF) showed that adding a neprilysin 
inhibitor (sacubitril) to a renin-angiotensin system blocker (and other standard therapy) 
reduced morbidity and mortality in ambulatory patients with chronic HF with reduced 
ejection fraction (HFrEF). In PARADIGM-HF, valsartan combined with sacubitril (a so-
called ARNI) was superior to the current gold standard of an ACEI, specifically enalapril, 
reducing the risk of the primary composite outcome of cardiovascular (CV) death or first HF 
hospitalization by 20% and all-cause death by 16%. Following the results of PARADIGM-HF, 
sacubitril/valsartan was approved by American and European regulatory authorities for the 
treatment of HFrEF. The burden of HF in Asia is substantial, both due to the huge population 
of the region and as a result of increasing CV risk factors and disease. Both the prevalence 
and mortality associated with HF are high in Asia. In the following review, we discuss the 
development of sacubitril/valsartan, the prototype ARNI, and the available evidence for its 
efficacy and safety in Asian patients with HFrEF.
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INTRODUCTION
Heart failure (HF) is a major global public health problem affecting an estimated 26 million 
people around the world.1) Asia accounts for more than 60% of the global population and 
more than two-thirds of the continent's countries are categorized as low- and middle-income 
countries. The increasing burden of cardiovascular (CV) disease in Asia is usually attributed 
to the increasing prevalence of risk factors such as obesity and diabetes.2-4) Consequently, 
the burden of HF has also increased, with prevalence estimates in Asia ranging from 1–5%, 
compared to 1–2% in Europe and North America. The overall prevalence in is estimated to be 
4.2 million in China and 1.3–4.6 in India.2-5) Moreover, unlike the West, where HF incidence 
rates have been stabilizing, the incidence of HF continues to rise in Asia, with an estimated 
500,000 new cases in China alone and another 0.5–1.8 million new cases in India each year.3) 
As a result of its large population, and the changing epidemiology of CV risk factors and disease 
in the region, more people are now living with HF in Asia than anywhere else in the world.
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Of added concern, Asian patients with HF are younger and show worse survival than the 
global average.2)3) It has also been suggested that there may be differences between Asians 
and other races in the tolerability, efficacy and safety of CV drugs, potentially diminishing 
their value.6)7)
The most recent breakthrough in the pharmacological management of HF was the demonstration 
that adding a neprilysin inhibitor (sacubitril) to a renin-angiotensin system blocker (and other 
standard therapy) reduced morbidity and mortality in patients with chronic, symptomatic, 
ambulatory HF with reduced ejection fraction (HFrEF). In the Prospective comparison of 
Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor 
(ACEI) to Determine Impact on Global Mortality and morbidity in HF trial (PARADIGM-HF), 
valsartan combined with sacubitril (ARNI) was superior to the current gold standard of an ACEI, 
specifically enalapril, reducing the risk of the primary composite outcome of CV death or first 
HF hospitalization by 20% and all-cause death by 16%.8) The results of PARADIGM-HF led to the 
approval of sacubitril/valsartan by American and European regulatory authorities, among others, 
for the treatment of HFrEF and its recommendation in international guidelines.9)10)
In light of the considerable burden of HFrEF and disease associated mortality in Asia, the 
purpose of this article is to review the development of ARNIs and the evidence for their 
efficacy and safety in Asian patients with HFrEF.
NATRIURETIC PEPTIDES AND NEPRILYSIN
Myocardial damage, most commonly as a result of poorly controlled hypertension, 
myocardial ischaemia or infarction, results in activation of the renin-angiotensin-aldosterone 
system (RAAS). Whilst initially compensatory to help maintain cardiac output, prolonged 
and sustained RAAS activation can have detrimental effects including increasing cardiac 
afterload due to vasoconstriction, promoting myocardial fibrosis and fluid retention 
secondary to an anti-natriuretic action. Ultimately these processes become deleterious and 
result in the development of the syndrome of HF and its progressive worsening over time.
The natriuretic peptides (NPs) are a family of vasoactive peptides which are released by 
the heart, in response to increased myocardial wall stress, and from blood vessels and the 
kidneys. The NPs help to nullify the harmful effects of an overactive RAAS. The first NP to 
be described was atrial NP (ANP), when in 1981, de Bold et al.11) demonstrated the increased 
urinary sodium and water excretory effect of atrial extracts. Subsequently, B-type NP 
(BNP), C-type NP (CNP) and urodilatin were identified, sharing the beneficial vasodilatory, 
natriuretic, anti-fibrotic and anti-hypertrophic properties of ANP.12)
The potential benefits of the NPs, including amelioration of the effects of RAAS overactivity, 
led to several lines of research into how these peptides might be used therapeutically. One 
obvious approach was short-term intravenous administration of supra-physiological does of 
exogenous NP in patients hospitalised with decompensated HF. However, in 2 trials neither 
nesiritide (a recombinant form of BNP) nor ularitide (a recombinant form of urodilatin) 
reduced mortality or re-hospitalization.13)14)
The alternative, and ultimately successful, approach was to augment level of endogenous NPs 
by reducing their elimination which occurs through 2 major pathways. One is through a NP 
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clearance receptor (NPRC or NPRC3) and the other is through degradation by the enzyme 
neprilysin (also known as membrane metallo-endopeptidase or neutral endopeptidase [NEP]), 
a membrane bound endopeptidase found in many tissues, most prominently in the kidney.15)16)
It is important to note that neprilysin also plays a role in the degradation several other 
peptides including bradykinin, adrenomedullin, substance P and calcitonin, apelin, 
glucagon-like peptide-1, vasoactive intestinal peptide, and enkephalins and these other 
substrates may contribute to the benefits of neprilysin inhibition.17)18)
NEPRILYSIN INHIBITION
Roques and colleagues in 1980 reported the first neprilysin inhibitor, thiorphan in animal 
models with demonstration of favourable hemodynamic and hormonal responses.19)20) 
Early reports showed that acute inhibition of neprilysin with oral racecadotril (formerly 
acetorphan) and intravenous candoxatrilat demonstrated stimulation of natriuresis and 
diuresis along with increases in circulating ANP levels in humans without any associated 
deleterious activation of RAAS or sympathetic activity as observed with loop diuretics.21-24) 
Furthermore, it was also seen that candoxatrilat and ecadotril reduced pulmonary capillary 
wedge pressure in patients with HF.21)23)
However, it was subsequently demonstrated that chronic dosing with candoxatril did not lead 
to a sustained reduction in blood pressure and development of the drug was consequently 
halted.25) The amelioration of the hypotensive action of this agent likely resulted from 
accumulation of angiotensin II, the breakdown of which was inhibited by candoxatril, and 
which offset the vasodilatory effects of NP accumulation.26)27) In retrospect, this finding 
demonstrated the need to combine neprilysin inhibition with blockade of the renin-
angiotensin system.
ANGIOTENSIN CONVERTING ENZYME-NEUTRAL 
ENDOPEPTIDASE INHIBITION
The first approach to combining neprilysin inhibition with renin-angiotensin system 
blockade was using molecules that inhibited both ACE and NEP, the most studied of which 
was omapatrilat.28)
In the Inhibition of Metalloprotease by Omapatrilat in a Randomized Exercise and 
Symptoms Study (IMPRESS) in HF trial, omapatrilat was compared to lisinopril to assess 
for improvement in functional capacity and clinical outcomes in 573 patients with HFrEF.29) 
While there was no significant difference seen in the primary outcome of exercise tolerance, 
a positive trend was seen in favour of omapatrilat in reducing the composite of death, 
admission or discontinuation of study treatment for worsening HF.
Two years later, the results of the Omapatrilat Versus Enalapril Randomized Trial of Utility 
in Reducing Events (OVERTURE) trial, a randomised controlled trial of omapatrilat 40 mg 
once daily compared to enalapril 10 mg twice daily, were published.30) There was no benefit 
of omapatrilat over enalapril in reduction of the primary endpoint of all-cause death or HF 
hospitalization. However, a nominally statistically significant 9% reduction in the secondary 
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endpoint of all-cause death and CV hospitalization was seen in patients randomized to 
receive omapatrilat. Moreover, in a post hoc analysis of the primary end point using the 
definition used in the Studies Of Left Ventricular Dysfunction (SOLVD) treatment trial 
there was an 11% lower risk in patients treated with omapatrilat (nominal, p=0.012).30) In 
retrospect, it also appeared that the single large daily dose of omapatrilat used in OVERTURE 
led to excessive hypotension and study drug discontinuation, while at the same time 
failed to provide sustained 24-hour inhibition of either neprilysin or the renin-angiotensin 
system. Together, these considerations suggested that, used in the right way, combined 
neprilysin and renin-angiotensin system inhibition might still be useful in HF. However, 
further development of omapatrilat was halted because of an excessively high rate of serious 
angioedema, particularly in the Omapatrilat Cardiovascular Treatment Assessment Versus 
Enalapril trial (OCTAVE) in hypertension where 2.2% of patients randomized to omapatrilat 
had angioedema compared to 0.7% of those randomized to enalapril.31) The higher rate 
of angioedema observed with omapatrilat was felt to be secondary to the accumulation of 
bradykinin, resulting from combined ACE and neprilysin inhibition (because both enzymes 
breakdown bradykinin). Omapatrilat was later found to also inhibit aminopeptidase-P, 
another key enzyme involved in degradation of bradykinin.32)
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS
The solution to the problem of safely combining neprilysin and renin-angiotensin system 
inhibition was solved by using an angiotensin receptor blocker (ARB), instead of an ACE 
inhibitor, and the development of sacubitril/valsartan.
Sacubitril/valsartan (originally named LCZ696) is the first in class ARNI, and is a 1:1 
combination of AHU377 (sacubitril) and an ARB (valsartan).33) Upon oral administration, 
sacubitril/valsartan dissociates and sacubitril is converted to its active metabolite sacubitrilat. 
Sacubitrilat and valsartan have half-lives of approximately 12 and 9.9 hours respectively and 
given twice daily ensure sustained neprilysin and RAAS inhibition over the 24-hour period.34) 
The valsartan formulation in sacubitril/valsartan is more bioavailable than conventional 
valsartan, with a 40% higher systemic exposure per mg of drug.35) Consequently, the target 
dose of sacubitril/valsartan (97/103 mg twice daily) gives plasma concentrations of valsartan 
equivalent to 160 mg twice daily of the conventional compound (the dose as studied in the 
Valsartan Heart Failure Trial [Val-HeFT]).36) This dose also gives a sustained increase in cyclic 
guanosine monophosphate, reflecting the second-messenger response to the increase in 
natriuretic (and possibly other) peptides resulting from neprilysin inhibition by sacubitrilat.37)
PROSPECTIVE COMPARISON OF ANGIOTENSIN 
RECEPTOR-NEPRILYSIN INHIBITOR WITH ANGIOTENSIN 
CONVERTING ENZYME INHIBITOR TO DETERMINE 
IMPACT ON GLOBAL MORTALITY AND MORBIDITY IN 
HEART FAILURE (PARADIGM-HF) TRIAL
PARADIGM-HF was designed to test the efficacy and safety of adding a neprilysin inhibitor 
(sacubitril) to a renin-angiotensin system blocker (and other standard therapy), compared 
with a renin-angiotensin system blocker (and other standard therapy) alone. Specifically, 
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sacubitril/valsartan 97/103 mg twice daily was compared to enalapril 10 mg twice daily.8) The 
choice of comparator, enalapril 10 mg twice daily, was based on the evidence from the SOLVD-
Treatment trial, the only large-scale, long-term, trial in a broad ambulatory HFrEF population, 
demonstrating superiority of and ACE inhibitor compared to placebo in reducing morbidity and 
mortality in HFrEF.38) For this reason enalapril 10 mg twice daily has been the “gold-standard” 
comparator in other trials and is the most studied ACE inhibitor in HFrEF trials (Table 1).
Patients were recruited between 2009 and 2012. All patients underwent a sequential run-
in period first with enalapril 10 mg twice daily followed by sacubitril/valsartan 97/103 mg 
twice daily for a total of 6–8 weeks. If no unacceptable side-effects were seen, patients were 
randomized 1:1 in a double-blind fashion to either sacubitril/valsartan 97/103 mg twice daily 
or enalapril 10 mg twice daily and followed up for occurrence of prespecified outcomes (or 
adverse events). PARADIGM-HF was terminated early in March 2014 on the recommendation 
of the Data Monitoring Committee due to overwhelming benefit observed with sacubitril/
valsartan therapy. The median duration of follow-up in PARADIGM-HF was 27 months.
CLINICAL EFFICACY OF SACUBITRIL/VALSARTAN IN 
PARADIGM-HF
Sacubitril/valsartan significantly reduced the risk of the primary composite outcome (hazard 
ratio [HR], 0.80; 95% confidence interval [CI], 0.73–0.87) and each of its components i.e. CV 
death (HR, 0.80; 95% CI, 0.71–0.89) and HF hospitalization (HR, 0.79; 95% CI, 0.71–0.89). 
Equal and significant reductions in the risk of the 2 major modes of CV death, sudden death 
and death from worsening HF, were also observed, and there was a 16% (95% CI, 7–24%) 
reduction in the risk of all-cause mortality.39)
Hence, for every 1,000 patients switched from enalapril to sacubitril/valsartan, there would 
be 46 fewer primary composite endpoint events, 27 fewer first HF hospitalisations, 31 fewer 
CV deaths and 28 fewer deaths from any cause over a follow-up of 27 months.
In addition, subsequent post-hoc analyses of PARADIGM-HF have shown no difference in 
the benefit of therapy with sacubitril/valsartan compared to enalapril according to age or to 
geographical region of enrolment (which will be discussed more with respect to Asia in later 
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Table 1. Characteristics of large trials in HF with enalapril
Trial No. of patients assigned to enalapril Target dose (mg) Mean daily dose (mg)
CONSENSUS (1987)54) 127 20 bid 18.4
SOLVD-T (1991)38) 1,285 10 bid 16.6
SOLVD-P (1992)55) 2,111 10 bid 16.7
V-HeFT II (1991)56) 403 10 bid 15.0
OVERTURE (2002)30) 2,884 10 bid 17.7
CARMEN (2004)57) 190 enalapril only 10 bid 16.8
191 enalapril plus carvedilol 10 bid 14.9
CIBIS-3 (2005)58) 505 enalapril first 10 bid 17.2
505 bisoprolol first 10 bid 15.8
ATMOSPHERE (2016)59) 2,336 enalapril only 5–10 bid 18.6
2,340 aliskiren plus enalapril 5–10 bid 19.1
ATMOSPHERE = Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure; CARMEN = Carvedilol 
ACE-Inhibitor Remodelling Mild CHF EvaluatioN; CIBIS = Cardiac Insufficiency Bisoprolol Study; CONSENSUS = 
Cooperative North Scandinavian Enalapril Survival Study; HF = heart failure; OVERTURE = Omapatrilat Versus 
Enalapril Randomized Trial of Utility in Reducing Events; SOLVD = Studies Of Left Ventricular Dysfunction; V-HeFT 
= Vasodilator-Heart Failure Trial.
sections).40)41) No other significant treatment effect interactions were seen in any of the other 
prespecified sub-groups or in relation to background drug or device therapy.8)42)
SAFETY AND TOLERABILITY OF SACUBITRIL/VALSARTAN 
IN PARADIGM-HF
Patients randomized to sacubitril/valsartan had significantly more hypotension than patients 
randomized to enalapril (14% vs. 9%; p<0.001) even though study-drug discontinuation as a 
result of hypotension was very rare and not significantly different between the treatment groups 
(0.9% vs. 0.7%; p=0.380). No significant difference in the rate of angioedema was reported 
(19 patients vs. 10 patients; p=0.130). Renal dysfunction, hyperkalaemia and cough were less 
commonly reported with sacubitril/valsartan compared to enalapril. Dementia and cognition 
related adverse events were not increased by sacubitril/valsartan in PARADIGM-HF.43)
REGULATORY APPROVAL AND STATISTICAL ROBUSTNESS 
OF RESULTS
The results of PARADIGM-HF were swiftly followed by regulatory approval of sacubitril/
valsartan for use in patients with HFrEF and conforming to the main inclusion criteria used 
in the trial. Regulatory approval of a new drug requires that its effectiveness and safety be 
demonstrated in either 2 trials with a 2-sided p value<0.05, or a single, large, internally 
consistent multicentre study with a p value<0.00125. PARADIGM-HF was a large (8,399 
patients), highly statistically significant (p value=0.0000004), internally consistent (lack of 
subgroup interaction), multicentre (sites in 47 countries) study with large treatment effects 
on morbidity and mortality. As a result of the robustness of the results of PARADIGM-HF it 
has been considered unethical to conduct a second large clinical trial with sacubitril/valsartan 
in patients HFrEF. With a p value of 0.0000004 for the primary composite outcome, the 
chance that sacubitril/valsartan is not superior to enalapril is less than one in a million.44)
On the basis of a single trial providing evidence of benefit, the American College of Cardiology 
(ACC) and the European Society of Cardiology guidelines have afforded sacubitril/valsartan 
a class I, level of evidence B treatment recommendation for use in HFrEF to reduce HF 
hospitalization and mortality in patients who remain symptomatic despite pharmacotherapy 
with ACE/ARB, a beta blocker and a mineralocorticoid antagonist.9)10) A meta-analysis of 
the 3 trials (PARADIGM-HF, IMPRESS, and OVERTURE) comparing combined neprilysin/
RAAS inhibition to RAAS inhibition alone in HFrEF, reported a significant pooled HR in 
reducing the risk of a composite endpoint of all-cause mortality or HF hospitalisation (HR, 
0.86; 95% CI, 0.76–0.97).45) Based on the results of this meta-analysis, as well as the degree 
of statistical certainty of benefit reported in PARADIGM-HF, we believe it can be reasonably 
argued that the body of evidence in favour of neprilysin inhibition supports a level of evidence A 
recommendation for treatment with sacubitril/valsartan in patients with symptomatic HFrEF, 
with now additional support for comParIson Of sacubitril/valsartaN versus Enalapril on Effect on 
nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF; see below).
PARADIGM-HF required patients to be tolerant of a dose of an ACE-inhibitor or ARB equivalent 
to enalapril 10 mg/day prior to enrolment. Several trials now support the use of sacubitril/
valsartan in ACE-inhibitor or ARB naïve patients including those stabilised from presentations 
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of acutely decompensated HF (a proportion of which we first or “de novo” presentations). The 
ACC guidance permits prescription of sacubitril/valsartan to ACEI/ARB naïve patients, a strategy 
which is supported by the results of the TITRATION and TRANSITION studies.46)47) Sacubitril/
valsartan was also found to result in a greater reduction in the N-terminal prohormone of BNP 
levels, compared to enalapril, among patients hospitalized for acute decompensated HF in the 
PIONEER-HF trial.48) A significant reduction in risk of rehospitalization for HF was also seen, 
although the trial was not powered for clinical outcomes.
There are a number of ongoing studies to assess the efficacy and safety of sacubitril/valsartan 
in other populations. Among them, the 2 that require mention here are the Prospective 
Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction 
(PARAGON-HF; NCT01920711) trial and the Prospective ARNI vs. ACE Inhibitor Trial to 
Determine Superiority in Reducing HF Events After MI (PARADISE-MI; NCT02924727).49) 
PARAGON-HF will evaluate the efficacy of sacubitril/valsartan compared to valsartan in 
reducing morbidity and mortality in patients with HF with preserved ejection fraction 
(HFpEF). It is the largest and the most globally representative HFpEF clinical trial to date and 
the results are expected this year.50) PARADISE-MI will assess the effect of sacubitril/valsartan 
compared to ramipril in reducing the occurrence of the composite endpoint of CV death, 
HF hospitalization and outpatient HF in post-acute MI patients with left ventricular systolic 
dysfunction and/or pulmonary congestion with no prior history of chronic HF.
ASIANS IN THE PARADIGM-HF TRIAL
A total of 1,487 patients were enrolled from 9 countries in the Asia-Pacific region in PARADIGM-
HF, accounting for 17.7% of the total cohort.8) For the purposes of this review, we have further 
divided Asia in PARADIGM-HF into 3 regions (East, South, and South-East Asia; Figure 1) and 
considered only those living in these countries who self-reported as being of Asian race.
A prior post-hoc analysis of PARADIGM-HF by region showed that patients from Asia were the 
youngest, had the lowest body mass index, lowest systolic blood pressure, reported a better 
quality of life and had fewer comorbidities.41) These findings were largely replicated in the 
Asian subgroups that we have analysed for this review and are shown in Table 2. In the analysis 
presented by Kristensen et al.,41) patients from Asia were most likely to receive digoxin and less 
likely to receive all other drugs and device therapies at the time of randomisation. It was also 
reported that while the risk of the primary composite end-point was highest in patients from 
Asia compared to North America (HR, 1.39; 95% CI, 1.06–1.80), there was no difference in 
treatment effect seen overall (p value for interaction-primary composite outcome=0.50).41)
CLINICAL EFFICACY OF SACUBITRIL/VALSARTAN IN 
ASIANS IN THE PARADIGM-HF TRIAL
The Asian patients presented in this analysis were followed up for a median of 26 months. 
Across all the groups examined, event rates per 100-person years were lower in patients 
randomized to sacubitril/valsartan compared to enalapril (Figure 2). Overall, South Asians 
had a lower rate of hospitalization for HF and higher mortality when compared to the other 
groups, and overall mortality due to CV or any cause was highest in Asians compared to the 
total PARADIGM-HF cohort.
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Importantly, no difference was seen between the benefits of treatment in Asians and the total 
PARADIGM-HF cohort or between the different regions of Asia (Figure 3).
TOLERABILITY AND SAFETY OF SACUBITRIL/VALSARTAN 
IN ASIANS IN THE PARADIGM-HF TRIAL
Concerns regarding potential differences in drug tolerability and safety in Asians, compared 
to non-Asians, possibly secondary to physical characteristics such as a lower body weight 
and smaller size, have led the advocation of lower doses of drugs in Asian patients.6) Indeed, 
the ongoing Prospective comparison of ARNI with ACE inhibitor to determine the noveL 
beneficiaL trEatment vaLue in Japanese Heart Failure patients (PARALLEL-HF) trial in 
Japanese patients with HFrEF has lower run-in doses for both sacubitril/valsartan (100 mg 
BD with no up-titration) and enalapril (5 mg BD).51) However, the achieved doses of the 
2 study treatments in PARADIGM-HF were similar in Asians to those in the overall trial 
patients. Mean daily dose of sacubitril/valsartan was 374.7±62.7 mg in the entire PARADIGM-
HF cohort (compared with a target dose of 400 mg daily). The achieved daily dose was 
373.88±66.0 mg in all Asians, 367.6±69.5 mg in East Asians, 374.2±71.8 mg in South Asians 
and 384.4±41.3 mg in South -East Asians. The mean daily dose of enalapril was 18.9±2.9 mg 
in PARADIGM-HF overall, and 19.0±2.9 mg, 18.8±3.1 mg, 19.1±2.9 mg, and 17.1±2.3 mg, in 
the Asian patient groups described above.
The reportedly high incidence of cough with ACEIs in Asians has led to ARBs becoming the 
preferred means of blocking the renin-angiotensin system in these individuals with HF or 
476https://e-kcj.org https://doi.org/10.4070/kcj.2019.0136
Sacubitril/Valsartan in Asian Patients
China
353
Hong Kong
23
Philippines
223
Malaysia
12
Thailand
39
India
621
Singapore
32
South Korea
80
Taiwan
86
East Asia
South Asia
South-East Asia
Figure 1. Number of patients of Asian patients by region enrolled in PARADIGM-HF (Asian race only). 
PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with Angiotensin converting 
enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial.
hypertension.52) In PARADIGM-HF, Asian patients randomized to sacubitril/valsartan overall 
had fewer complaints of cough compared to those randomized to enalapril, consistent with 
the overall findings in the total trial cohort (Table 3). Also, as seen in the total PARADIGM-HF 
population, hypotension was more common among Asians randomized to sacubitril/valsartan 
compared to enalapril. In Asian patients, as in the trial as a whole, patients randomized to 
sacubitril/valsartan had fewer adverse events leading to treatment discontinuation.
During the follow-up period, patients in Asia assigned to receive sacubitril/valsartan showed 
greater improvement in quality of life as indicated by the KCCQ clinical summary at 8 months 
compared to those receiving enalapril. Accordingly, more patients receiving enalapril had a 
clinically significant fall in KCCQ score at 8 months compared to sacubitril/valsartan (Table 4).
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Table 2. Baseline characteristics of all patients and by Asian regions enrolled in PARADIGM-HF
Overall (n=8,399) All Asia (n=1,469) East Asia (n=542) South Asia (n=621) South-East Asia (n=306)
Age (years) 63.8±11.4 57.8±11.9 59.7±11.9 57.1±11.7 56.0±11.8
Sex (female) 1,832 (21.8) 287 (19.5) 96 (17.7) 134 (21.6) 57 (18.6)
SBP (mmHg) 121±15 117±15 116±14.6 117±13 119±17
Heart rate (bpm) 72±12 75±11 73±12 77±9 75±13
BMI (kg/m2) 28.1±5.5 24.3±4.1 25.0±3.8 23.5±3.9 24.6±4.8
Serum creatinine (mg/dL) 1.12±0.3 1.06±0.3 1.05±0.3 1.03±0.3 1.15±0.3
Clinical features of HF
Ischemic cardiomyopathy 5,036 (60.0) 855 (58.2) 209 (38.6) 449 (72.3) 197 (64.4)
LVEF (%) 29.5±6.2 28.1±5.9 29.5±5.3 27.5±5.8 27.0±6.6
Median NT-proBNP (pg/mL) 1,615 (888–3,231) 1,731 (914–3,700) 1,775 (934–3,828) 1,530 (832–3,105) 2,147 (1,077–4,679)
Median KCCQ CSS 80 (63–92) 89 (79–96) 91 (82–97) 87 (77–96) 89 (71–97)
NYHA class
I 389 (4.6) 119 (8.1) 23 (4.3) 37 (6.0) 59 (19.3)
II 5,919 (70.6) 1,164 (79.3) 426 (78.7) 503 (81.0) 235 (76.8)
III 2,018 (24.1) 182 (12.4) 92 (17.0) 78 (12.6) 12 (3.9)
IV 60 (0.7) 3 (0.2) 0 (0.0) 3 (0.5) 0 (0.0)
Medical history
Hypertension 5,940 (70.7) 714 (48.6) 276 (50.9) 258 (41.5) 180 (58.8)
Diabetes 2,907 (34.6) 510 (34.7) 176 (32.5) 230 (37.0) 104 (34.0)
Atrial fibrillation 3,091 (36.8) 247 (16.8) 155 (28.6) 32 (5.2) 60 (19.6)
MI 3,634 (43.3) 503 (34.2) 150 (27.7) 262 (42.2) 91 (29.7)
Stroke 725 (8.6) 89 (6.1) 42 (7.7) 13 (2.1) 34 (11.1)
Hospitalization for HF 5,274 (62.8) 888 (60.4) 415 (76.6) 288 (46.4) 185 (60.5)
Pretrial use of ACEI 6,532 (77.8) 996 (67.8) 334 (61.6) 491 (79.1) 171 (55.9)
Pretrial use of ARB 1,892 (22.5) 474 (32.3) 207 (38.2) 132 (21.3) 135 (44.1)
Current smoker 1,208 (14.4) 967 (14.0) 152 (28.0) 50 (8.1) 39 (12.7)
Clinical features
Dyspnoea at rest 309 (3.7) 19 (1.3) 4 (0.7) 11 (1.8) 4 (1.3)
Dyspnoea on effort 7,207 (86.0) 1,146 (78.2) 420 (77.6) 570 (91.8) 156 (51.3)
PND 399 (4.8) 40 (2.7) 8 (1.5) 27 (4.3) 5 (1.7)
Orthopnoea 608 (7.3) 53 (3.6) 5 (0.9) 26 (4.2) 22 (7.3)
JVD 818 (9.8) 83 (5.7) 18 (3.3) 62 (10.0) 3 (1.0)
Peripheral oedema 1,748 (20.8) 175 (11.9) 23 (4.3) 203 (32.7) 28 (9.2)
Treatment at randomization
Diuretic 6,738 (80.2) 1,080 (73.5) 372 (68.6) 545 (87.8) 163 (53.3)
Digitalis 2,539 (30.2) 652 (44.4) 219 (40.4) 296 (47.7) 137 (44.8)
Beta-blocker 4,671 (55.6) 825 (56.2) 359 (66.2) 285 (45.9) 181 (59.2)
ICD 1,243 (14.8) 26 (1.8) 23 (4.2) 1 (0.2) 2 (0.7)
CRT 574 (6.8) 42 (2.9) 38 (7.0) 3 (0.5) 1 (0.3)
Values are presented as mean±standard deviation or median (interquartile range) or number (%).
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; CRT = cardiac resynchronization therapy; ICD = 
implantable cardioverter defibrillator; JVD = jugular venous distension; KCCQ CSS = Kansas city cardiomyopathy questionnaire clinical summary score; LVEF 
= left ventricular ejection fraction; MI = myocardial infarction; NT-proBNP = N terminal pro brain natriuretic peptide; NYHA = New York Heart Association; 
PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with Angiotensin converting enzyme inhibitor to Determine Impact on 
Global Mortality and Morbidity in Heart Failure trial; PND = paroxysmal nocturnal dyspnoea; SBP = systolic blood pressure.
478https://e-kcj.org https://doi.org/10.4070/kcj.2019.0136
Sacubitril/Valsartan in Asian Patients
Table 3. Adverse events by treatment in all patients and by Asian regions enrolled in PARADIGM-HF
Overall All Asia East Asia South Asia South-East Asia
Enalapril 
(n=4,212)
Sac/val 
(n=4,187)
Enalapril 
(n=731)
Sac/val 
(n=738)
Enalapril 
(n=271)
Sac/val 
(n=271)
Enalapril 
(n=307)
Sac/val 
(n=314)
Enalapril 
(n=153)
Sac/val 
(n=153)
Cough 601 (14.3) 474 (11.3) 211 (28.9) 156 (21.1) 68 (25.1) 50 (18.5) 83 (27.0) 57 (18.2) 60 (39.2) 49 (32.0)
Hypotension 388 (9.2) 588 (14.0) 51 (7.0) 88 (11.9) 21 (7.7) 39 (14.4) 23 (7.5) 33 (10.5) 7 (4.6) 16 (10.5)
Hyperkalaemia 455 (10.8) 395 (9.4) 57 (7.8) 49 (6.6) 14 (5.2) 17 (6.3) 38 (12.4) 28 (8.9) 5 (3.3) 4 (2.6)
Angioedema 11 (0.3) 20 (0.5) 2 (0.3) 4 (0.5) 0 (0.0) 2 (0.7) 1 (0.3) 1 (0.3) 1 (0.7) 1 (0.7)
Any AE leading to study drug 
discontinuation
129 (3.1) 79 (1.9) 13 (1.8) 10 (1.4) 6 (2.2) 3 (1.1) 2 (0.7) 3 (1.0) 5 (3.3) 4 (2.6)
AE = adverse event; PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with Angiotensin converting enzyme inhibitor to 
Determine Impact on Global Mortality and Morbidity in Heart Failure trial; Sac/val = Sacubitril/valsartan.
Table 4. Change in KCCQ clinical summary score by treatment in all patients and by Asian regions enrolled in PARADIGM-HF
Overall All Asia East Asia South Asia South-East Asia
Enalapril 
(n=4,212)
Sac/val 
(n=4,187)
Enalapril 
(n=731)
Sac/val 
(n=738)
Enalapril 
(n=271)
Sac/val 
(n=271)
Enalapril 
(n=307)
Sac/val 
(n=314)
Enalapril 
(n=153)
Sac/val 
(n=153)
KCCQ clinical summary 
score rise ≥5–8 months
1,113 (26.60) 1,132 (27.20) 131 (18.10) 130 (17.70) 42 (15.60) 47 (17.40) 79 (26.20) 76 (24.30) 10 (6.50) 7 (4.60)
KCCQ clinical summary 
score fall ≥5–8 months
1,283 (30.70) 1,124 (27.00) 143 (19.70) 118 (16.00) 61 (22.60) 35 (13.00) 65 (21.50) 70 (22.40) 17 (11.10) 13 (8.50)
KCCQ = Kansas city cardiomyopathy questionnaire; PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with Angiotensin 
converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure trial; Sac/val = Sacubitril/valsartan.
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Figure 2. Event rates per 100 patient years by treatment in all patients and by Asian regions enrolled in PARADIGM-HF. 
HF = heart failure; PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor with Angiotensin converting enzyme inhibitor to 
Determine Impact on Global Mortality and Morbidity in Heart Failure trial.
IMPLEMENTATION OF SACUBITRIL/VALSARTAN IN 
ASIAN GUIDELINES
Guidelines for management of HF vary across different Asian regions.53) We reviewed the 
most up to date HF management guidelines in the Asian countries in PARADIGM-HF to 
see if there were any recommendations pertaining to sacubitril/valsartan. There were very 
few countries with up to date clinical guidelines for HF and out of those only 3 countries 
recommended sacubitril/valsartan in their guidelines for management of HFrEF in their 
patients (Table 5).
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Overall
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Figure 3. Treatment effects by Asian regions in PARADIGM-HF. 
CI = confidence interval; PARADIGM-HF = Prospective comparison of Angiotensin Receptor-neprilysin inhibitor 
with Angiotensin converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart 
Failure trial. 
*Interaction p value for Asia subgroups.
CONCLUSIONS
In PARADIGM-HF, adding a neprilysin inhibitor (sacubitril) to a renin-angiotensin system 
blocker (valsartan) reduced morbidity and mortality, compared to a renin-angiotensin 
system blocker (enalapril) alone, in ambulatory patients with chronic HFrEF. The data 
presented in this review support the use of sacubitril/valsartan in Asian patients with chronic, 
symptomatic, and ambulatory HFrEF.
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